MoonLake Immunotherapeutics EBIT

MoonLake Immunotherapeutics posts a EBIT of $-190M as of June 2026. That compares with $-140M in the prior-year period — down 39.3% year over year. That is below the sector sector average of $2.6T. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, MoonLake Immunotherapeutics's EBIT was $-140M. The latest reading is $-190M — a 39.3% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a EBIT near $2.6T is typical. MoonLake Immunotherapeutics's $-190M is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

EBIT is one piece of MoonLake Immunotherapeutics's financial statement story. At $-190M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for MLTX's EBIT usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $2.6T), and (3) consistency with growth and profitability. This page covers the first two; MoonLake Immunotherapeutics's other metric pages and overview cover the third.